Clinical Trials
6
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2004
Active, not recruiting
1
16.7%
Completed
2
33.3%
Recruiting
3
50.0%
No approval data available
- Digital inhalers can detect significant physiologic changes up to two weeks before COPD exacerbations occur, potentially enabling earlier clinical intervention. - The ProAir Digihaler captured three key metrics that changed significantly before acute exacerbations: inhalation volume, inhalation duration, and time to peak inhalation. - These physiologic changes preceded the typical increase in rescue inhaler use, suggesting patients may perceive symptoms after lung function deterioration begins. - The pilot study involved 40 current smokers with COPD and recorded 23 acute exacerbation events, demonstrating the technology's potential for remote patient monitoring.
- Bronchiectasis management is shifting from standardized treatment algorithms to precision medicine approaches that target specific patient phenotypes and symptoms. - The COPD Foundation has established 27 bronchiectasis and nontuberculous mycobacteria Centers of Excellence with plans to expand to over 150 centers nationwide. - Current clinical trials are investigating targeted therapies including DPP1 inhibition, Type 2 inflammation treatments, and CFTR modulators for non-cystic fibrosis bronchiectasis. - A "treatable traits" approach focusing on individual patient characteristics is improving management outcomes and quality of life for bronchiectasis patients.
- Thirona and the COPD Foundation have partnered to analyze over 10,000 patients in the COPDGene cohort using AI-powered quantitative CT imaging technologies to identify crucial biomarkers for COPD phenotyping. - The research will utilize Thirona's LungQ analytical capabilities, including Bronchial-Artery Analysis and Mucus Plug Quantification, to better understand COPD's heterogeneity and improve precision medicine approaches. - With COPD affecting 390 million people globally and only 15-20% of patients responding predictably to current treatments, this collaboration aims to enable more personalized therapies and enhance patient engagement through clearer disease visualization.
